Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.29), $0.07 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $26.94 million versus the consensus estimate of $27.96 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.